The Health Technology Assessment (HTA) process in Saudi Arabia is evolving rapidly. It began a few years ago with the launch of Vision 2030. The country has developed a system that draws from global best practices, particularly from the UK, Canada, and the Nordic countries, while tailoring it specifically to Saudi Arabia's needs. Although the process is still in its early stages and has been informal so far, some products have already undergone review through the formal HTA mechanism. The official rollout of the formal process is expected by the end of the year. While the exact timelines remain uncertain, the informal assessments in place make it crucial to stay updated on this process for any new products entering the market.
Saudi Arabia is truly at the forefront of medical innovation, not just in the region but on a global scale. With a population of 36 million, it boasts one of the strongest social security systems for its citizens worldwide. This system heavily invests in healthcare infrastructure, making it one of the largest contributors to the nation's development. As a result, citizens enjoy comprehensive access and full reimbursement for any new therapies that enter the market. Saudi Arabia is a crucial market because not only does it have a fully reimbursed population, but it also has systems and processes that are rapidly developing to align with global standards.
Additionally, there is potential for products launching in Saudi to match US prices, unlocking transformative market value without compromising regional competitiveness.
Pharma BP and FIECON collaborate closely and regularly on this process, having developed a robust mechanism to make it happen. We typically start by reviewing the EU model available to us, and then Pharma BP begins by gathering local data and generating evidence. When information on local costs and epidemiology is accessible, we conduct a literature review to collect it. Alternatively, we initiate data generation studies to gather localized information, which is then validated with stakeholders in Saudi Arabia.
Once all the data is collected, it is passed to the FIECON team, who integrate it into the available models. These models are customized specifically for Saudi Arabia. The end result is a model that is HTA-ready for the Saudi market.
Overall, the process is smooth, and projects like this typically take about three months. It's proven to be a highly effective collaboration and a great way to develop the necessary models.
Pharma BP is a consulting and market access firm focusing on the life sciences sector within the MEA region. Based in Dubai, Pharma BP support the clients in defining how to get to market successfully in MEA region, with the broadest access and at commercially sustainable price points.
To learn more about FIECON's Partnership with Pharma BP, please visit: https://www.fiecon.com/campaigns/saudi-arabia
